What Tomorrow Bio does

Tomorrow Bio is a Berlin-based private biotech founded in 2020 by Dr. Emil Kendziorra and Fernando Azevedo Pinheiro that provides human and pet cryopreservation services aimed at potential future revival. The company serves affluent individuals who reject the inevitability of death from currently incurable diseases and want a biological backup plan for advances in future medical technology. As of February 2026, Tomorrow Bio reports over 1,000 full members and 26 Fellows across 45+ countries, with 20 human patients and 10 pets cryopreserved since inception.

The company's core technology centers on field cryoprotection: custom-built Generation 3 biostasis ambulances outfitted as mobile operating rooms allow the only provider worldwide to begin cryopreservation procedures immediately after legal death declaration, before transport to long-term storage. The vitrification process achieves a glass-like transition at -196°C in liquid nitrogen to prevent ice crystal formation, with CT-scan-based quality assurance verifying perfusion quality for each case. Long-term storage is handled by the European Biostasis Foundation (EBF), a financially independent non-profit in Switzerland selected for political stability and rule of law.

Tomorrow Bio operates a multi-stream revenue model combining recurring membership subscriptions (€50/month or €500/year in Europe, with a €15,000 lifetime option credited toward cryopreservation), one-time cryopreservation fees (€200,000 whole-body or €75,000 brain-only for European members), and life insurance partnerships that most members use to finance the procedure. Distribution is direct-to-consumer via online sign-up and free consultations, with the company's own medical teams serving Mainland EU, UK/Ireland, and three US states (New York, California, Florida). The company expanded to the United States in July 2024 and secured a €5 million seed round in May 2025 to fund nationwide US expansion, increased research, and operational scaling.

Name

Tomorrow Bio

Legal name

Tomorrow Biostasis GmbH

Website

https://tomorrow.bio

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Tomorrow Bio is a Berlin-based biotech founded in 2020 that provides human and pet cryopreservation services to affluent individuals seeking life extension. The company uses field cryoprotection technology with custom-built mobile ambulances and Swiss-based indefinite liquid nitrogen storage.

Ownership category

akta.pro rank

Product category

Human Cryopreservation Services

NAICS

Blood and Organ Banks (621991), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Cold Chain, Cryopreservation & Biologics Storage/Handling Technologies (HLAAAJAN)

akta.pro secondary industries

Cryopreservation, Biobanking & Cell Banking (Cord/Adipose/MSC) (HLAMANAJ), Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats) (HLAGAIAJ), Cryogenic Logistics (LN2 Dry Shippers, -150°C) (HLAGAMAB)

Keywords

• Human cryopreservation services
• Biostasis preservation
• Cryonics membership
• Vitrification procedures
• Emergency standby services

Headquarters

HQ city

Berlin

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Infrastructure, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Membership Fees: Recurring membership fees provide constant medical standby and access to the Tomorrow.bio community. Membership options include monthly (€50/month), annual (€500/year), or lifetime (€15,000) plans in Europe, with lifetime amount deducted from cryopreservation costs.
2. Cryopreservation Services: One-time fees for cryopreservation procedure including dispatch, standby until death, cryopreservation, transport to Switzerland, and indefinite storage. Whole-body cryopreservation costs €200,000 (member) or €230,000 (non-member) in Europe; brain-only costs €75,000 (member) or €115,000 (non-member).
3. Life Insurance Partnerships: Most members finance cryopreservation through term life insurance, with the company offering guidance on insurance options. Insurance fees start at €20/month for whole-body coverage and €6/month for brain-only coverage.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Tomorrow Bio provides human cryopreservation (biostasis) services that preserve whole bodies or brains at -196°C after legal death, with the goal of potential future revival when medical technology advances. The company delivers 24/7 emergency standby and field cryoprotection via custom-built biostasis ambulances, performs vitrification-based procedures, and provides indefinite storage at a Swiss facility operated by the European Biostasis Foundation. Members pay recurring subscription fees and one-time cryopreservation fees, with optional pet cryopreservation and life insurance funding.

Product overview

Tomorrow Bio is a cryopreservation (cryonics/biostasis) company offering human and pet body preservation services with the goal of potential future revival. The core product portfolio includes whole-body and brain-only cryopreservation services, pet cryopreservation, and 24/7 emergency standby/medical response services. Long-term storage is provided at the European Biostasis Foundation facility in Switzerland. The company also offers a membership subscription program for ongoing standby coverage, a custom ambulance program for field cryoprotection, and life extension consulting services. All services are supported by field cryoprotection technology using German-engineered equipment and Swiss-based storage infrastructure.

Differentiator

Problem solved

Functional benefit

Brands

• European Biostasis Foundation (EBF): Non-profit organization responsible for long-term patient storage in Switzerland. Operates independently from Tomorrow Bio but is part of the company's organizational structure for cryopreservation services.

Products and services

• Human Cryopreservation (Whole-Body) Whole-body cryopreservation service that preserves the entire human body at ultra-low temperatures after legal death, with the aim of potential future revival when medical technology advances. Available to members (€200,000 in Europe / $220,000 in US) and non-members (€230,000 in Europe).
• Brain-Only Cryopreservation (Neuropreservation) Brain-only cryopreservation service that preserves only the brain at ultra-low temperatures, offering a more affordable alternative to whole-body preservation. Available to members (€75,000 in Europe / $80,000 in US) and non-members (€115,000 in Europe / $110,000 in US).
• Pet Cryopreservation Cryopreservation services for pets, allowing members to preserve their animal companions for potential future revival alongside human family members. 1 pet membership is included free with human membership.
• Emergency Standby Services 24/7 medical team standby and rapid response dispatch service, sending equipped biostasis ambulances and response teams to members upon signs of imminent death to begin field cryoprotection.
• Long-Term Storage (European Biostasis Foundation) Indefinite patient storage at a purpose-built facility in Switzerland operated by the European Biostasis Foundation, maintained with liquid nitrogen at -196°C without electricity requirements.
• Membership Program Subscription membership providing 24/7 medical standby, equipment maintenance, welcome box, community access, priority support, and exclusive member events. Starting at €50/month or €500/year, with lifetime option at €15,000 (deducted from cryopreservation cost).
• Tomorrow Ambulance Program Custom-built biostasis ambulances outfitted as mobile operating rooms enabling whole-body field cryoprotection. Generation 3 ambulances available to partners for €120,000 including all medical and cryoprotection equipment.

Quantifiable outcome

• Cryopreserved 20 patients and 10 pets with documented case reports available

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core and minor.

• European Biostasis Foundation (EBF)coreStrategic or Co-development PartnerNon-profit foundation in Switzerland handles long-term patient storage. EBF is completely financially independent from Tomorrow Bio. The foundation ensures patient security regardless of Tomorrow Bio's operational status. Patients are stored at EBF facilities in liquid nitrogen indefinitely.
• Tomorrow Ambulance Program PartnersminorStrategic or Co-development PartnerIndividuals or groups can fund dedicated biostasis ambulances located near them. Partners cover equipment and material costs (€120,000 for Generation 3 ambulance), while Tomorrow Bio builds, relocates, and maintains the ambulances. Optional local team training provided free.
• Travel Partner OrganizationsminorChannel Partner/ Reseller/ DistributorPartner organizations handle standby coverage for members traveling outside core regions (3+ weeks). Subject to availability and organized through Tomorrow Bio coordination.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Alcor Life Extension Foundation: Alcor is the largest and longest-established US-based human cryopreservation provider (founded 1972), offering whole-body and neuropreservation services with long-term storage in Arizona. It is the most direct competitor to Tomorrow Bio, sharing the same core service (human cryopreservation) and target customer (affluent longevity-curious individuals), though lacking Tomorrow Bio's field cryoprotection capability.
• Cryonics Institute: Cryonics Institute is a Michigan-based non-profit cryopreservation provider (founded 1976) offering lower-cost whole-body preservation. It directly competes with Tomorrow Bio on the same core service but uses older, fixed-facility procedures without mobile field cryoprotection, positioning it as the budget alternative.
• Oregon Cryonics: Oregon Cryonics is a smaller US-based human cryopreservation provider offering whole-body and neuro preservation. It competes directly in the same product category as Tomorrow Bio with similar pricing, but at smaller scale and without Tomorrow Bio's European presence or mobile cryoprotection fleet.
• KrioRus: KrioRus is a Russia-based cryopreservation provider (founded 2005) and was the first to operate outside the US. It offers whole-body and neuropreservation at lower price points than Tomorrow Bio but with less advanced field infrastructure and significant geopolitical/regulatory headwinds that limit cross-border service.
• Yinfeng Cryonics: Yinfeng Cryonics is China's first human cryopreservation provider, founded in 2015 in Shandong. It offers comparable services (whole-body and neuropreservation) and is growing rapidly in the Asian market, representing a geographic competitor that limits Tomorrow Bio's expansion in East Asia.
• Southern Cryonics: Southern Cryonics is an Australia-based cryopreservation provider serving Australia and New Zealand, founded in 2017. It offers the same core human cryopreservation service as Tomorrow Bio and represents a regional competitor in the Oceania market where Tomorrow Bio currently lacks infrastructure.

Others

• European Biostasis Foundation: The European Biostasis Foundation is a Swiss-based non-profit that handles Tomorrow Bio's long-term patient storage as a financially independent entity. It is comparable because it shares the same organizational ecosystem and patient base, though it functions as the storage arm rather than a direct commercial competitor.
• 21st Century Medicine: 21st Century Medicine is a research organization that has pioneered many of the cryopreservation techniques (including vitrification methods) underlying modern cryonics. It is comparable as a research and development contributor to the broader cryopreservation field but does not offer direct human cryopreservation services.

Broad incumbents

• Cryoport Systems: Cryoport is a US-listed provider of cryogenic logistics, cold-chain shipping, and biostorage services primarily serving the life sciences and biopharma industries. It is comparable to Tomorrow Bio's cryogenic transport and storage infrastructure but operates in the B2B life sciences market rather than direct-to-consumer human cryopreservation.
• BioLife Solutions: BioLife Solutions is a US-listed biopreservation tools and storage services company serving cell and gene therapy and regenerative medicine markets. It is comparable because it supplies cryopreservation media, biopreservation technology, and storage services — overlapping with Tomorrow Bio's equipment and storage capabilities but serving the broader biotech industry.

Market position

Strengths6 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights10 records

Customer concentration

• Xx.com/tomorrowbio
• YouTubeyoutube.com/@TomorrowBio
• Facebookfacebook.com/tomorrowbiostasis
• LinkedInlinkedin.com/company/tomorrow-biostasis
• Instagraminstagram.com/tomorrowbio

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tomorrow Bio